Literature DB >> 18373228

Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis.

S W Y Tsang1, P T Francis, M M Esiri, P T H Wong, C P L H Chen, M K P Lai.   

Abstract

RATIONALE: Neuropsychiatric behaviours in Alzheimer's disease (AD) patients have been associated with neocortical alterations of presynaptic cholinergic and muscarinic M2 receptor markers. In contrast, it is unclear whether non-M2 muscarinic receptors have a role to play in AD behavioural symptoms.
OBJECTIVES: To correlate the alterations of neocortical postsynaptic muscarinic receptors with clinical features of AD.
MATERIALS AND METHODS: [(3)H]4-DAMP were used in binding assays with lysates of Chinese hamster ovary (CHO) cells stably transfected with M1-M5 receptors. [(3)H]4-DAMP was further used to measure muscarinic receptors in the postmortem orbitofrontal cortex of aged controls and AD patients longitudinally assessed for cognitive decline and behavioural symptoms.
RESULTS: [(3)H]4-DAMP binds to human postmortem brain homogenates and M1-, M3-, M4- and M5-transfected CHO lysates with subnanomolar affinity. Compared to the controls, the [(3)H]4-DAMP binding density is reduced only in AD patients with significant psychotic symptoms. The association between reduced [(3)H]4-DAMP binding and psychosis is independent of the effects of dementia severity or neurofibrillary tangle burden.
CONCLUSIONS: This study suggests that the loss of non-M2 muscarinic receptors in the orbitofrontal cortex may be a neurochemical substrate of psychosis in AD and provides a rationale for further development of muscarinic receptor ligands in AD pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18373228     DOI: 10.1007/s00213-008-1124-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

1.  The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.

Authors:  Maibritt B Andersen; Anders Fink-Jensen; Linda Peacock; Jes Gerlach; Frank Bymaster; Jens August Lundbaek; Thomas Werge
Journal:  Neuropsychopharmacology       Date:  2003-03-26       Impact factor: 7.853

2.  Neuropathologic correlates of apathy in Alzheimer's disease.

Authors:  Gad A Marshall; Lynn A Fairbanks; Sibel Tekin; Harry V Vinters; Jeffrey L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  2006-01-02       Impact factor: 2.959

Review 3.  On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease.

Authors:  H J Koch; S Haas; T Jürgens
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

4.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

5.  Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease.

Authors:  Shirley W Y Tsang; Justine Pomakian; Gad A Marshall; Harry V Vinters; Jeffrey L Cummings; Christopher P L-H Chen; Peter T-H Wong; Mitchell K P Lai
Journal:  Neurobiol Aging       Date:  2006-07-07       Impact factor: 4.673

6.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

7.  Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease.

Authors:  S Tekin; M S Mega; D M Masterman; T Chow; J Garakian; H V Vinters; J L Cummings
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

Review 8.  Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence.

Authors:  H C Fibiger
Journal:  Trends Neurosci       Date:  1991-06       Impact factor: 13.837

Review 9.  Acetylcholine: a neurotransmitter for learning and memory?

Authors:  A Blokland
Journal:  Brain Res Brain Res Rev       Date:  1995-11

10.  Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys.

Authors:  M J Callahan; J J Kinsora; R E Harbaugh; T M Reeder; R E Davis
Journal:  Neurobiol Aging       Date:  1993 Mar-Apr       Impact factor: 4.673

View more
  5 in total

Review 1.  Psychosis in Alzheimer's disease.

Authors:  Patrick S Murray; Sanjeev Kumar; Mary Ann A Demichele-Sweet; Robert A Sweet
Journal:  Biol Psychiatry       Date:  2013-10-06       Impact factor: 13.382

2.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

3.  Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.

Authors:  Gursharan Chana; Chad A Bousman; Tammie T Money; Andrew Gibbons; Piers Gillett; Brian Dean; Ian P Everall
Journal:  Front Cell Neurosci       Date:  2013-06-26       Impact factor: 5.505

4.  Behavioral and psychological symptoms of dementia.

Authors:  J Cerejeira; L Lagarto; E B Mukaetova-Ladinska
Journal:  Front Neurol       Date:  2012-05-07       Impact factor: 4.003

Review 5.  Psychosis in Alzheimer's Disease.

Authors:  Clive Ballard; Helen C Kales; Constantine Lyketsos; Dag Aarsland; Byron Creese; Roger Mills; Hilde Williams; Robert A Sweet
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-13       Impact factor: 5.081

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.